Navigation Links
Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
Date:7/30/2008

tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2008 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.

CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: http://www.championsbiotechnology.com


'/>"/>
SOURCE Champions Biotechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
7. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
8. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
9. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
10. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
11. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader ... webinar next week entitled "No Account Left Behind!  ... to Help Keep Its Account Reconciliations in Good Shape ... The webinar, geared at finance, accounting, audit and compliance ...
(Date:6/19/2013)... BioConvergence team members Curtis Strother ... 2013’s BioLogistics Summit in San Francisco earlier this ... Chain IQ and IQPC, addressed the increasingly complex ... part, attributed to current trends of globalization, outsourcing, ... trends is an increase in movement, which is ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased ... measurement of sulfur in ultra-low sulfur diesel (ULSD) using ... EDXRF analyzer . The analysis detailed in Rigaku Application ... This International Standard specifies an energy dispersive X-ray ... content in automotive gasoline. , Regulations around the world ...
(Date:6/19/2013)... 19, 2013 Express Diagnostics Int’l, Inc., ... announced that it has received Class III medical device ... its DrugCheck® NxStep Onsite Drug Screen Cup ... rapid screening device in near-patient settings, such as physicians’ ... received Health Canada Class III approval for 24 different ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3
... Encorium Group, Inc. (Nasdaq: ENCO ), a full service ... for many of the world,s leading pharmaceutical and biotechnology companies, today ... Nasdaq stating that since it had not, as of the date ... June 30, 2009, it was then no longer in compliance with ...
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , , , , ... PPHM ) today announced that it will release its financial results for ... 7:00 a.m. EDT and will host a conference call and webcast to ... , Peregrine,s senior management will discuss financial results for ...
Cached Biology Technology:Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 2Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing 3Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results 2
(Date:6/19/2013)... June 19, 2013 MedNet Solutions , ... study management systems, is pleased to announce its participation ... June 23-27 in Boston .  This ... recognized leader in cloud-based eClinical solutions, has exhibited at ... showcasing iMedNet™ EDC , MedNet,s latest, ...
(Date:6/19/2013)... the most perfectly spherical large objects in nature may ... new study. It appears in ACS, journal Langmuir ... Julyan Cartwright, Antonio G. Checa and Marthe Rousseau point ... have perhaps the most perfectly spherical, or ball-like, shape ... without a microscope. Pearls develop as nacre (mother of ...
(Date:6/19/2013)... 2012, the European Medicines Agency (EMA) approved the ... ever gene therapy for clinical use in the ... developed AAV-LPL S447X for the treatment of a ... (LPLD) which affects approximately one or two out ... life-threatening inflammations of the pancreas. Afflicted individuals carry ...
Breaking Biology News(10 mins):MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2No danger of cancer through gene therapy virus 2
... Cones, holes and temporary traffic lights the scourge of ... together to reduce the misery of motorists caused by ... under the tarmac. They,ll reveal how new technology will ... digging. A sector-wide seminar at The University of ...
... New Orleans, LA Research led by David Worthylake, PhD, ... Sciences Center New Orleans, may help lay the groundwork for ... cancer. The research will be published in the May 29, ... During the transition from a localized tumor to metastatic ...
... NOT trying to assert their dominance over their canine ... at the University of Bristol,s Department of Clinical Veterinary ... Applications and Research . The researchers spent six ... rehoming centre, and reanalysing data from studies of feral ...
Cached Biology News:Reducing the roadworks 2Reducing the roadworks 3LSUHSC research describes function of key protein in cancer spread 2Using 'dominance' to explain dog behavior is old hat 2
... BAS-2500 is ideal for ... Biology (1D electrophoresis, 2D ... Macroarrays); Pharmacokinetics & Toxicology ... layer chromatography); Physical and ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
Biology Products: